KR20150132362A - Pcsk9의 소분자 조절물질 및 그것의 사용 방법 - Google Patents

Pcsk9의 소분자 조절물질 및 그것의 사용 방법 Download PDF

Info

Publication number
KR20150132362A
KR20150132362A KR1020157029032A KR20157029032A KR20150132362A KR 20150132362 A KR20150132362 A KR 20150132362A KR 1020157029032 A KR1020157029032 A KR 1020157029032A KR 20157029032 A KR20157029032 A KR 20157029032A KR 20150132362 A KR20150132362 A KR 20150132362A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
unsubstituted
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157029032A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 구아이
쉘던 크레인
니콜라스 라샹스
진-프랑수아 치아손
보우이 린 트루옹
패트릭 라콩브
캐서린 스코리
나빌 지 세이다
Original Assignee
에이다에레이타, 리미티드 파트너쉽
아모르캠 홀딩스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이다에레이타, 리미티드 파트너쉽, 아모르캠 홀딩스 아이엔씨. filed Critical 에이다에레이타, 리미티드 파트너쉽
Publication of KR20150132362A publication Critical patent/KR20150132362A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020157029032A 2013-03-15 2014-03-14 Pcsk9의 소분자 조절물질 및 그것의 사용 방법 Withdrawn KR20150132362A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792249P 2013-03-15 2013-03-15
US61/792,249 2013-03-15
PCT/CA2014/050255 WO2014139008A1 (en) 2013-03-15 2014-03-14 Small molecule modulators of pcsk9 and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20150132362A true KR20150132362A (ko) 2015-11-25

Family

ID=51535727

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029032A Withdrawn KR20150132362A (ko) 2013-03-15 2014-03-14 Pcsk9의 소분자 조절물질 및 그것의 사용 방법

Country Status (10)

Country Link
US (1) US20160031935A1 (enrdf_load_stackoverflow)
EP (1) EP2961765A4 (enrdf_load_stackoverflow)
JP (1) JP2016511274A (enrdf_load_stackoverflow)
KR (1) KR20150132362A (enrdf_load_stackoverflow)
CN (1) CN105431447A (enrdf_load_stackoverflow)
AU (1) AU2014231330A1 (enrdf_load_stackoverflow)
BR (1) BR112015023761A2 (enrdf_load_stackoverflow)
CA (1) CA2905237A1 (enrdf_load_stackoverflow)
HK (1) HK1222864A1 (enrdf_load_stackoverflow)
WO (1) WO2014139008A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
US10034892B2 (en) * 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
US20170290806A1 (en) * 2014-09-08 2017-10-12 Temple University-Of The Commonwealth System Of Higher Education PCSK9 Inhibitors and Methods of Use Thereof
MX384944B (es) * 2015-03-20 2025-03-14 Univ Aarhus Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas".
EP3464336B1 (en) 2016-06-01 2022-03-16 Athira Pharma, Inc. Compounds
KR102449308B1 (ko) 2016-06-24 2022-10-04 에프. 호프만-라 로슈 아게 심혈관 질환의 치료를 위한 조성물 및 방법
GB2567210B (en) 2017-10-06 2020-01-15 Rolls Royce Plc A bladed disk
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
LV15544A (lv) * 2019-07-01 2021-01-20 Latvijas Organiskās Sintēzes Institūts Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori
WO2024163598A2 (en) * 2023-01-31 2024-08-08 Brandeis University Peptides comprising thioester groups, including depsipeptide thioesters, methods of making, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266525A1 (en) * 1996-09-24 1998-04-02 Charles Winston Saunders Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP2204181A3 (en) * 2002-04-30 2010-09-22 Trustees Of Tufts College Protease inhibitors
US20100233177A1 (en) * 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AU2011223795B2 (en) * 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR20140132367A (ko) * 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제

Also Published As

Publication number Publication date
US20160031935A1 (en) 2016-02-04
EP2961765A4 (en) 2016-11-09
EP2961765A1 (en) 2016-01-06
CN105431447A (zh) 2016-03-23
BR112015023761A2 (pt) 2017-07-18
HK1222864A1 (zh) 2017-07-14
CA2905237A1 (en) 2014-09-18
AU2014231330A1 (en) 2015-10-01
JP2016511274A (ja) 2016-04-14
WO2014139008A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
KR20150132362A (ko) Pcsk9의 소분자 조절물질 및 그것의 사용 방법
KR102481876B1 (ko) 니트릴-함유 항바이러스 화합물
CN110809467B (zh) Sestrin-gator2相互作用的调节剂及其用途
WO2022021841A1 (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
US11692008B2 (en) Preparation and uses of reactive oxygen species scavenger derivatives
JP6063567B2 (ja) Ｐａｄ４阻害剤としての２−（アザインドール−２−イル）ベンズイミダゾール
AU2018205019C1 (en) Inhibitors of transglutaminases
US20240158405A1 (en) Selective modulators of mutant lrrk2 proteolysis and associated methods of use
JP2008519843A (ja) 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
EA005740B1 (ru) Карбаматные ингибиторы каспазы и их использование
CN113727966A (zh) 泛硫醇衍生物及其用途
KR20210097154A (ko) Hiv 요법에 유용한 화합물
CN111356699A (zh) 活性氧清除剂的制备及用途
KR20100126762A (ko) 세포내 효소 및 수용체 조절
US20150232420A1 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
JP2022512687A (ja) Ｃｇｒｐアンタゴニストのプロドラッグ
WO2021094436A1 (en) Substituted hydantoinamides as adamts7 antagonists
WO1998046582A1 (en) Protease inhibitors
RU2786722C1 (ru) Нитрилсодержащие противовирусные соединения
Bhattarai et al. CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
CN116375713A (zh) 一种dclk1蛋白降解靶向嵌合体及其应用
CN120344538A (zh) 作为cGAS抑制剂的环状吡啶衍生物
EA046321B1 (ru) Нитрилсодержащие противовирусные соединения
WO2019184744A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid